Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study)

Randomised controlled trial of Antiglucocorticoid augmentation (metyrapone) of antiDepressants in Depression (ADD Study)

Background: Depressed patients who do not respond to second-line antidepressant drugs are characterised as suffering from treatment-refractory depression (TRD). Chronic psychosocial stress hypothalamic–pituitary–adrenal (HPA) axis dysfunction is associated with attenuated responses to antidepressant...

Full description

Bibliographic Details
Main Authors: I Nicol Ferrier, Ian M Anderson, Jane Barnes, Peter Gallagher, Heinz CR Grunze, Peter M Haddad, Allan O House, Tom Hughes, Adrian J Lloyd, Chrysovalanto Mamasoula, Elaine McColl, Simon Pearce, Najma Siddiqi, Baxi Sinha, Chris Speed, Nick Steen, June Wainwright, Stuart Watson, Fiona H Winter, R Hamish McAllister-Williams, the ADD Study Team
Format: Article
Language:English
Published: NIHR Journals Library 2015-06-01
Series:Efficacy and Mechanism Evaluation
Subjects:
randomised controlled trial
antiglucocorticoid
augmentation
metyrapone
antidepressants
depression
add study
treatment-refractory depression
Online Access:https://doi.org/10.3310/eme02040

Internet

https://doi.org/10.3310/eme02040

Similar Items